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Abstract The aim of this study was to investigate whe-
ther neutrophil-guided dose escalation of anthracycline–
cyclophosphamide-containing chemotherapy (ACC) for
breast cancer is feasible, in order to optimize outcome.
Breast cancer patients planned for 3-weekly ACC were
enrolled in this study. The first treatment cycle was ad-
ministered in a standard BSA-adjusted dose. The absolute
neutrophil count was measured at baseline and at day 8, 11
and 15 after administration of ACC. For patients with none
or mild (CTC grade 0–2) neutropenia and no other dose-
limiting toxicity, we performed a 10–25 % dose escalation
of the second cycle with the opportunity to a further
10–25 % dose escalation of the third cycle. Thirty patients
were treated in the adjuvant setting with either FE100C
(n = 23) or AC (n = 4), or in the palliative setting with
FAC (n = 3). Two out of 23 patients (9 %) treated with
FEC did not develop grade 3–4 neutropenia after the first
treatment cycle. Dose escalation was performed in these
two patients (30 % in one and 15 % in the other patient).
During dose escalation, there were no complications like
febrile neutropenia. No patients treated with FAC or AC
could be escalated, since all of them developed grade 3–4
neutropenia. We conclude that asymptomatic grade 3–4
neutropenia is likely to be achieved in the majority of
patients with breast cancer treated with ACC according to
presently advocated BSA-based dose levels. Escalation of
currently advocated ACC doses without G-CSF, with a
target of grade 3–4 neutropenia, is feasible, but only pos-
sible in a small proportion of patients. EudraCT
2010-020309-33.
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Introduction
Both anthracyclines and cyclophosphamide are highly effec-
tive drugs in the treatment of breast cancer [1, 2]. According to
international guidelines, anthracycline–cyclophosphamide-
containing chemotherapy (ACC) is part of (neo) adjuvant
treatment schedules for early stage or locally advanced breast
cancer [3]. Furthermore, in the setting of metastatic disease,
ACC is often used as palliative treatment [4, 5].
Although highly effective, not all patients benefit from
ACC. The cumulative dose of anthracyclines administrated
is important. From randomized controlled trials, it is clear
that higher ‘standard dose’ of anthracyclines for early
breast cancer improves patient survival compared to lower
‘standard dose’ [6]. On the other hand, a reason for dif-
ferences in efficacy among patients who have had a similar
dose of anthracyclines administered could be the large in-
ter-individual (between patients) as well as the intra-indi-
vidual (within patients) variability in pharmacokinetic (PK)
parameters [7]. Interestingly, hematological toxicity is
strongly associated with the absolute dose of anthracycline
and might be useful as a surrogate measure of the
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anthracycline dose [6]. In accordance, some retrospective
studies indeed have shown that breast cancer patients given
adjuvant chemotherapy but not attaining at least moderate
hematological toxicity have a worse prognosis compared to
those with more toxicity [8–11].
The current standard of dosing ACC is guided by body
surface area (BSA) with an a posteriori dose reduction of all
component drugs in case of excessive toxicity (e.g., febrile
neutropenia). Dose escalation among patients without toxi-
city is, however no standard of care. The administration of an
inappropriately low dose of chemotherapy is therefore not
recognized, leaving patients that might benefit from an in-
creased dose unidentified. The percentage of breast cancer
patients receiving a suboptimal dose of ACC is unknown, as
well as the amount of under-dosing in these individuals.
In the present study, we addressed the feasibility of a
simple tool for neutrophil-guided dose adaptation of ACC
(without primary G-CSF support), among female breast
cancer patients treated with ACC for either palliative or
curative intention. The aim was to reach nadir absolute
neutrophil count (ANC) of B1.0 9 10e9/L with recovery
to C1.5 9 10e9/L at the time of the planned next treatment
cycle, without excessive hematological or non-hemato-
logical toxicity. In case successful dose escalation is pos-
sible in a substantial number of patients, this method is
valid and should be further developed and refined to be
ultimately tested on treatment efficacy in a prospective
randomized trial of neutrophil-guided versus standard
BSA-adjusted dosing.
Patients and methods
Participants
Chemotherapy-naive female breast cancer patients aged
C18 years and planned for treatment with at least three cycles
of ACC were identified at the Department of Medical On-
cology, Ikazia Hospital, Rotterdam, The Netherlands. Both
patients treated with curative as well as patients treated with
palliative intention were eligible. Patients with the following
chemotherapy regimens were eligible: FEC (fluorouracil
500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide
500 mg/m2), AC (doxorubicin 60 mg/m2, cyclophosphamide
600 mg/m2) or FAC (fluorouracil 500 mg/m2, doxorubicin
50 mg/m2, cyclophosphamide 500 mg/m2). Additionally,
patients should have a WHO performance status 0–1, life
expectancy[3 months, adequate peripheral blood cell counts
(leukocytes C4.0 9 10e9/L and ANC C2.0 9 10e9/L and
platelet count C150 9 10e9/L), adequate renal function
(defined as normal serum creatinine concentration and/or
estimated creatinine clearance C60 mL/min), adequate liver
function [defined as normal serum bilirubin concentration
(B17 lmol/L) and serum ASAT and ALAT B3 times the
upper limit of normal (B5 times the upper limit of normal in
case of hepatic metastases)], normal serum albumin con-
centration (35–50 g/L) and given written informed consent.
Women were excluded from participation if they had been
treated with chemotherapy previously, were unable to con-
sent with weekly follow-up for blood cell counts and toxicity
assessment, had symptomatic brain metastasis, had a history
of cardiac dysfunction, had uncontrolled arterial hypertension
(blood pressure systolic C180 mmHg and/or diastolic
C110 mmHg) and/or unstable angina pectoris. Ethical ap-
proval for this study was obtained through the Institutional
Review Boards, and all women signed the informed consent.
The study was conducted in full accordance with the princi-
ples of the Declaration of Helsinki and local regulations. The
trial adhered to the guidelines for good clinical practice and
the European Union Clinical Trial Directive.
Study design
This study was a prospective single-center feasibility study.
The first treatment cycle was given using standard BSA-
adjusted dosing. Following the administration of ACC,
ANC was evaluated in peripheral venous blood samples
obtained at days 8 (±1), 11 (±1) and 15 (±1), day 1 being
the day of chemotherapy administration. Hematological
and non-hematological toxicities were assessed weekly
according to the common toxicity criteria (CTC), version 3.
Subsequent cycles of ACC were given at 3-week intervals
provided that the patient had sufficiently recovered from
hematological and non-hematological toxicity. Sufficient
recovery of hematological toxicity was defined as an ANC
of C1.5 9 10e9/L and a platelet count of C100 9 10e9/L,
whereas sufficient recovery of non-hematological toxicity
was defined as CTC grade B1 (with the exception of
alopecia). In patients with nadir ANC C1.0 9 10e9/L and
maximum non-hematological toxicity CTC grade B2 dur-
ing the first cycle of ACC, the dose of cyclophosphamide
and the anthracycline (doxorubicin or epirubicin) was in-
creased with 10, 15 or 25 % according to a predefined
schedule based on neutrophil count on day 8 and day 15. In
patients treated with chemotherapy schedules including
fluorouracil (FAC or FEC), the dose of fluorouracil was not
escalated due to its negligible contribution to hemato-
logical toxicity in these combination regimens [7]. Patients
undergoing dose escalation of the second cycle of ACC
were candidates for a further (and final) dose escalation of
the third cycle of ACC following the same principles and
according to the same predefined schedule. Patients expe-
riencing excessive toxicity (i.e., febrile neutropenia,
symptomatic thrombocytopenia and/or grade 3–4 non-
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hematological toxicity with the exception of nausea and
vomiting) without previous dose escalation were treated
according to standard clinical practice. In case of excessive
toxicity after dose escalation, patients had to be retreated
with standard BSA-adjusted dose during subsequent treat-
ment cycles. Finally, all patients treated with C4 cycles of
ACC received standard BSA-adjusted dosing from the
fourth cycle onward. The study design is also outlined in
Fig. 1.
Statistical analysis
This study was designed as a pilot feasibility study. There-
fore, a useful sample size calculation was not appropriate.
We aimed to enter 30 patients. Successful dose escalation of
chemotherapy was our primary goal and was rather arbi-
trarily defined as a C15 % increase in anthracycline/cy-
clophosphamide dose without excessive hematological
(febrile neutropenia, grade 3–4 thrombocytopenia) or non-
hematological (grade 3–4) toxicity. We stated that if suc-
cessful dose escalation was possible in a significant pro-
portion of patients (at least three out of 30 patients), our
experimental method of neutrophil-guided dose escalation
could be feasible in daily clinical practice and should be
further developed and refined to be ultimately tested on
treatment efficacy in a prospective randomized trial of
neutrophil-guided versus standard BSA-adjusted dosing. If
successful dose escalation turned out to be possible in less
than three out of 30 patients, it is unlikely that this method
of dose escalation will have significant impact on treat-
ment efficacy, and this method should not be further
explored.
Furthermore inter-individual variation in ANC after
administration of the chemotherapy was assessed as coef-
ficient of variation (CV) for nadir ANC and for cumulative
neutrophil count [expressed as the sum of CTC grades of
neutropenia (0–4) on day 8, 11 and 15], addressing the
duration of neutropenia.
ACC cycle 1
Nadir ANC ≤ grade 2 and non-hematological toxicity ≤ grade 2
Yes No
Dose escalation depending 
on ANC on days 8 and 15
Further treatment according to 
standard practice
ACC cycle 2
Nadir ANC ≤ grade 2 and non-haematological toxicity ≤ grade 2  
Yes No
Further dose escalation depending 
on ANC on days 8 and 15
No further dose escalation
ACC: anthracycline-cyclophosphamide containing chemotherapy
ANC: absolute neutrophil count
Fig. 1 Study design.
ACC anthracycline–
cyclophosphamide-containing
chemotherapy, ANC absolute
neutrophil count
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Results
A total of 30 patients were entered in this study between
November 2010 and December 2013. Baseline character-
istics are outlined in Table 1. Median age was 55 years
(range 37–74 years). The majority of the patients were
treated for early breast cancer with either FEC (77 %) or
AC (13 %). Three patients (10 %) were treated with first-
line palliative chemotherapy in the form of FAC.
Dose escalation was feasible in two patients. Both patients
were treated with FEC for early breast cancer. So 2/23 (9 %) of
patients treated with FEC could be escalated, while no patients
treated with FAC or AC could be escalated. Both of the esca-
lated patients developed only grade 2 neutropenia (ANC
1.00–1.49 9 10e9/L) at day 15 of the first cycle and were
escalated with 15 % during the second cycle. One of these
patients reached grade 3 neutropenia (ANC 0.50–0.99 9 10e9/
L) in the second cycle, and no further escalation was performed.
The other patient developed only grade 2 neutropenia after the
second cycle and was further escalated with another 15 % in
cycle 3 (Fig. 2; Table 2). During dose escalation, there were no
complications like febrile neutropenia, grade 3–4 thrombocy-
topenia or increase in non-hematological toxicity. There were
no relevant differences in baseline characteristics between
escalated and non-escalated patients (Table 2).
For the whole group of patients, mean ANC at baseline was
5.32 9 10e9/L (range 2.66–10.52), on day 8 was3.72 9 10e9/L
(range 2.02–9.60), on day 11 was 0.80 9 10e9/L (range
0.05–2.11) and on day 15 was 0.53 9 10e9/L (range 0.03–3.94).
Nadir mean was 0.41 9 10e9/L (range 0.03–1.28) and was
reached on day 11 in seven patients and on day 15 in 23 patients.
Coefficient of variation (CV) for mean ANC nadir was 0.77.
Grade 3 neutropenia (ANC 0.50–0.99 9 10e9/L) or grade 4
neutropenia (ANC \0.50 9 10e9/L) after the first treatment
cycle was observed in 28 of the 30 patients. Two of them had
febrile neutropenia and were hospitalized. All patients had re-
covery of ANC to C1.5 9 10e9/L at the time of the planned next
treatment cycle. Duration of neutropenia expressed as mean
cumulative neutrophil count (the sum of CTC grades of neu-
tropenia on day 8, 11 and 15) was 6.4 with a CV of 0.24
(Table 3).
Incidence of grade 3–4 neutropenia was lower after the
second and third cycle of chemotherapy compared to after
the first cycle (proportion of grade 3–4 neutropenia in cycle
one, two and three, respectively, 94, 77 and 75 %, non-
significant, Table 4). In these figures, patients who under-
went dose escalation or used secondary G-CSF prophylaxis
were excluded.
Discussion
The ANCHOR study was designed based on the improved
survival found in a number of retrospective studies among
patients treated with adjuvant chemotherapy for early
breast cancer, who achieved a higher degree of hemato-
logical toxicity [6, 9–11]. In this pilot feasibility study
among breast cancer patients treated with currently ad-
vocated doses of ACC, neutrophil-guided dose escalation
was feasible. Dose escalation was possible in two out of
23 patients (9 %) treated with FEC, while dose escalation
was possible in none of the patients treated with FAC or
AC. Asymptomatic grade 3–4 neutropenia was achieved
in the majority of patients after the first cycle of ACC. It
seems therefore not useful to proceed with a large ran-
domized controlled trial on neutrophil-guided dose esca-
lation among patients with currently advocated doses of
ACC.
Previously, two other studies have also investigated the
feasibility of dose escalation of ACC, although they are
hardly comparable with our current study. In the first
study of tailored fluorouracil, epirubicin and cyclophos-
phamide (FEC) with primary granulocyte colony-s-
timulating factor (G-CSF) support, the dose of epirubicin
and cyclophosphamide could be escalated by 50 % or
more in more than half of the patients. Starting dose in
this study was fluorouracil 600 mg/m2, epirubicin 75 mg/
m2 and cyclophosphamide 900 mg/m2. Treatment with
nine cycles of tailored FEC with G-CSF support (median
cumulative dose of epirubicin was 780 mg/m2) was,
however, associated with an increased risk of acute
myeloid leukemia and myelodysplastic syndrome. There
were also more cardiac side effects in the tailored FEC
group. Tailored FEC with G-CSF support can therefore
not be advocated for clinical practice [12]. In our study,
the two patients in whom escalation of ACC was feasible
had a cumulative dose of epirubicin of 347 and 330 mg/
m2, respectively. In the second study by Edlund et al., the
Table 1 Baseline characteristics
Median age [years (range)] 55 (36–74)
Chemotherapy regime [n (%)]
FEC 23 (77)
FAC 3 (10)
AC 4 (13)
Tumor stage [n (%)]
Early 27 (90)
Metastatic 3 (10)
WHO performance score [n (%)]
WHO 0 25 (83)
WHO 1 5 (17)
Median height [cm (range)] 170 (155–184)
Median weight [kg (range)] 75 (53–100)
Median body surface are [m2 (range)] 1.9 (1.5–2.1)
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study design was comparable with our study; however, the
‘standard’ dose of epirubicin used in this study was sub-
stantially lower than in our study (60 mg/m2 vs 100 mg/m2,
respectively). In this study (n = 1535), patients who did not
reach leukopenia CTC grade 3 or 4 after a first cycle of
standard FEC (in this study fluorouracil 600 mg/m2,
epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2)
were randomized to a total of six courses of standard dosed
FE(60)C (n = 526) or a total of six cycles of FEC with
doses tailored to achieve grade 3 leukopenia (n = 521). The
relative dose intensity (defined as the given dose delivered
in the originally expected time/the expected dose in the
expected time) was increased by a factor of 1.31. Median
cumulative dose of epirubicin in the tailored dose group was
520 mg/m2. There was no excess of acute non-hemato-
logical toxicity [13].
It is important to mention that both these studies used
lower ‘standard’ doses of epirubicin compared to our study
(75 and 60 mg/m2, respectively). It can be concluded based
on these and our study that neutrophil-guided dose escala-
tion might be feasible in older regimens with lower ‘stan-
dard dose’ of epirubicin. With currently advocated doses
(epirubicin 100 mg/m2 and doxorubicin 50–60 mg/m2), it
is, however, not feasible to escalate a relevant proportion of
patients.
Interestingly, the two patients, who were escalated, were
both treated with epirubicin, while none of the patients
treated with doxorubicin could be escalated. This might be
due to chance. A real difference in hematological toxicity
between these two anthracycline can, however, not be ex-
cluded. When taking only the patients treated with epiru-
bicin into account, dose escalation was possible in 9 % of
Fig. 2 Absolute neutrophil
counts over time in the two
escalated patients
Table 2 Details of escalated
patients
ANC absolute neutrophil count
Patient A Patient B
Escalations 15 % in first cycle 15 % in first cycle
15 % in second cycle No further escalation in second cycle
Age (years) 47 55
Chemotherapy regime FEC FEC
Body surface are (m2) 1.9 1.8
Weight (kg) 75 75
Cycle 1 ANC baseline 7.05 9.35
Cycle 1 ANC nadir 1.28 1.21
Cycle 1 ANC nadir (day reached) 15 11
Cycle 2 ANC baseline (910e9/L) 3.13 6.88
Cycle 2 ANC nadir (910e9/L) 1.19 0.59
Cycle 2 ANC nadir, day reached 15 15
Med Oncol (2015) 32:113 Page 5 of 8 113
123
patients, not reaching the predefined 10 % which was
considered worthwhile enough for further exploration.
Furthermore, a trend was seen in a decreased proportion
of patient with grade 3–4 neutropenia over the subsequent
cycles. In our study, dose escalation was only permitted
when no grade 3–4 neutropenia was seen after cycle 1.
When we also had allowed patients to escalate based on
ANC nadir after the second cycle, five more patients could
have been escalated in the third cycle. One of the currently
advocated (neo)adjuvant chemotherapy regimens consists
of three cycles FEC (5FU 500; epiriubicin 100 and cy-
clophosphamide 500 mg/m2), followed by three cycles
docetaxel 100 mg/m2. In this regimen, cumulative anthra-
cycline dose is relatively low, with a low risk of car-
diotoxicity [14]. Since only three cycles of ACC are given,
it is of utmost importance to dose these cycles as high as
possible without unacceptable side effects. Further research
should therefore focus mainly on patients treated in
(neo)adjuvant setting and allow escalation also in subse-
quent cycles.
For most classical anticancer drugs, BSA-guided dosing
is still standard practice in clinical oncology. BSA-based
dosing of chemotherapy has largely resulted from its use in
the extrapolation of drug doses used in experimental ani-
mals to those considered safe as starting doses for phase I
clinical trials. However, a proper scientific rationale for
BSA-based dosing of anticancer drugs in human adult
cancer patients is lacking [15–17]. Furthermore, the use of
BSA does not reduce inter-individual variability in phar-
macokinetic parameters for the majority of investigated
anticancer drugs [18]. For irinotecan, it has been shown
that flat-fixed dosing does not result in increased pharma-
cokinetic/pharmacodynamic variability and could be safely
used [19]. Furthermore, for carboplatin, glomerular filtra-
tion rate-adjusted dosing has been widely accepted as
Table 3 Laboratory values, first cycle
Mean ANC
Baseline [910e9/L (range)] 5.32 (2.66–10.52)
Day 8 [910e9/L (range)] 3.72 (2.02–9.60)
Day 11 [910e9/L (range)] 0.80 (0.05–2.11)
Day 15 [910e9/L (range)] 0.53 (0.03–3.94)
Mean ANC nadir [910e9/L (range)] 0.41 (0.03–1.28)
Coefficient of variation (CV) 0.77
ANC nadir [N (%)]
Day 8 0 (0)
Day 11 7 (23)
Day 15 23 (77)
Neutropenia nadir [N (%)]
CTC grade 0 0 (0)
CTC grade 1 0 (0)
CTC grade 2 2 (7)
CTC grade 3 8 (27)
CTC grade 4 20 (67)
Mean cumulative neutrophil counta 6.4
Coefficient of variation 0.24
Febrile neutropenia [N (%)] 2 (7)
a Expressed as the sum of CTC grades of neutropenia (0–4) on day 8,
11 and 15
Table 4 ANC nadir in first three cycles of ACC
Cycle 1 (n = 30) Cycle 2 (n = 21a) Cycle 3 (n = 16b)
Mean ANC nadir [910e9/L (range)] 0.41 (0.03–1.28) 0.66 (0.09–1.50) 0.63 (0.06–1.57)
ANC nadir [N (%)]
Day 8 0 (0) 0 (0) 0 (0)
Day 11 7 (23) 2 (10) 5 (31)
Day 15 23 (77) 19 (90) 11 (69)
Neutropenia nadir [N (%)]
CTC grade 0 0 (0) 0 (0) 0
CTC grade 1 0 (0) 0 (0) 1 (6)
CTC grade 2 2 (7) 5 (24) 3 (19)
CTC grade 3 8 (27) 10 (48) 4 (25)
CTC grade 4 20 (67) 6 (29) 8 (50)
ANC absolute neutrophil count
a Exclusion of escalated patients (n = 2), patients with febrile neutropenia after the first cycle (n = 2) and patients with missing data (n = 5).
Besides the escalated patients, there were no patients with dose alterations in the second cycle
b Exclusion of escalated patients (n = 2), patients with febrile neutropenia after the first cycle (n = 2) and patients with missing data (n = 10).
There were no patients with febrile neutropenia after the second cycle. Besides the escalated patients, there were no patients with dose alterations
in the third cycle
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standard [20]. Although knowledge on pharmacogenetics
has rapidly been expanding, this had not led to many
practically applicable dosing algorithms for classical anti-
cancer drugs, while exposure to chemotherapy is influ-
enced by many other interacting factors [21, 22]. For
fluoropyrimidines, it has been suggested to adjust the dose
based on dihydropyrimidine dehydrogenase (DPYD)
genotype tests [23]. The method of dose adjustment guided
by plasma drug concentrations (therapeutic drug monitor-
ing, TDM) has not been used as standard practice, which is
largely due to the obscure relationship between plasma
drug concentrations and treatment effects [24, 25]. How-
ever, for the vast majority of classical anticancer agents,
BSA-guided dosing remains still standard practice. For
most (oral) targeted agents, flat-fixed dosing and a poste-
riori dose reduction in case of severe toxicity is a standard
practice. For these agents, the relation between dose and
outcome (both efficacy and safety) is even less clear,
compared to classical chemotherapy, due to both differ-
ences in molecular characteristics of the tumor as well as in
environmental and genetic factors.
Conclusion
In conclusion, inter-individual variability in hematological
toxicity with currently advocated doses of ACC in breast
cancer patients is limited. Escalation of currently advo-
cated ACC doses without G-CSF, with a target of grade
3–4 neutropenia, is feasible, but only possible in a
relatively small proportion of patients. Since no other
dosing algorithms are available for ACC, BSA-guided
dosing remains standard practice at this moment.
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